Semaglutide Pen 2mg- Adjustable Dose

Semaglutide is a long acting synthetic GLP-1 receptor agonist with a half-life of approximately 7 days, achieved through fatty acid chain conjugation enabling albumin binding and protection against DPP-4 enzymatic degradation. This 2mg adjustable dose pen delivers Semaglutide in a lower concentration presentation than CSD’s other Semaglutide formats: the 9.6mg prefilled pen at fixed 2.4mg doses and the iLab Pharma 10mg lyophilized vial. Providing researchers with the most conservative entry point into Semaglutide pen format research and the most granular low dose titration capability across CSD’s Semaglutide range.

The adjustable dose mechanism is the defining feature that differentiates this pen from the fixed dose 9.6mg prefilled pen presentation. Where the 9.6mg pen delivers four pre set 2.4mg doses suited to protocols operating at the higher end of the clinically referenced concentration range, the adjustable dose format allows researchers to dial precise sub 2mg increments from the 2mg total supply. Supporting initial dose response characterization at the lowest Semaglutide concentration points, titration protocols beginning at conservative doses before escalation, and research designs where fine grained control over GLP-1 receptor activation levels is a critical experimental variable.

CSD’s Semaglutide range now spans three distinct formats covering the full spectrum from low dose adjustable pen through to high volume lyophilized vial. This 2mg adjustable dose pen at the lowest concentration entry point, the 9.6mg fixed dose prefilled pen for standardized higher concentration administration, and the 10mg lyophilized vial for reconstitution controlled in vitro and parenteral research applications. The pure GLP-1 receptor selectivity of Semaglutide remains consistent across all three formats, positioning it as the single receptor reference standard against which CSD’s dual incretin GLP-2 TRZ and triple incretin GLP-3 RTA listings are compared in comparative receptor pathway research.

Every batch of CSD’s Semaglutide pen is third party lab tested for concentration accuracy and purity before being made available, with COA documentation available on request. Canada Steroid Depot has supplied Canadian customers with consistently verified, accurately dosed research compounds for years, and our Semaglutide range across all three formats represents the most complete GLP-1 receptor agonist sourcing available from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Store at 2–8°C away from direct light. Do not freeze. Keep upright. Intended for research purposes only.

Commonly researched alongside dual and triple incretin agonist compounds in comparative GLP-1 receptor pathway and metabolic activity studies. Browse CSD’s full peptide range for complete sourcing.